The role of molecular analyses in the diagnosis and treatment of non-small-cell lung carcinomas
Introduction
In 2011, lung cancer was the leading cause of cancer-related deaths worldwide.1 Unfortunately, median survival of patients with metastatic disease remains disappointing, with only a small fraction of patients surviving more than 2 years. Non-small-cell lung cancer (NSCLC) represents 85% of all lung cancer diagnoses and is a heterogeneous disease with several biological events driving tumor growth and progression. Enormous efforts in clinical trials over the last 10 years and harmonious cooperation between clinicians and basic scientists have led to the development of new molecularly driven therapies with unprecedented results in some subsets of patients.
The aim of this review is to discuss the role of molecular analysis in the diagnosis and treatment of advanced NSCLC to guide a personalized approach, with a particular focus on the new challenges faced by pathologists dealing with lung cancer.
Section snippets
Personalized treatment for NSCLC: The point of view of the medical oncologist
The last few years have been terribly exciting for clinicians treating patients with advanced NSCLC. After decades of slow progresses and “one-size-fits-all” approach, the era of personalized treatment has eventually arrived. For years, NSCLC patients have been treated with the same chemotherapy, without any clinical or biological selection, and inevitably disappointing results. Recently, we have learned that patient selection is extremely important to select the most appropriate treatment and
Pathologists and molecular analyses in the diagnosis of NSCLC
NSCLC has been considered for several years as one disease, while this definition included various histotype with different “druggable” oncogenic drivers, opening to personalized therapies and a multidisciplinary approach involving physicians, molecular biologists, pharmaceutical companies, as well as pathologists.32, 33, 34, 35, 36 Molecular analyses in NSCLC have been mainly focused on patient prognosis and in prediction of response to novel targeted therapies. Pathologists play a key role in
Pathologists, molecular analyses, and handling of tumor samples
More than 70% of non-small-cell lung cancer (NSCLC) patients present with unresectable advanced disease.127 In such advanced NSCLC patients, the diagnosis is generally achieved through minimally invasive procedures that usually retrieve small biopsies (trans-thoracic fine-needle biopsies and bronchial and trans-bronchial biopsies) or exclusively cytological samples (i.e., fine-needle aspiration and pleural or pericardial effusion), often just adequate to reach a diagnosis of malignancy.
Personalized treatment for NSCLC: The point of view of the molecular biologist
Recent progress in molecular diagnostics of NSCLC has identified epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) fusion proteins as key genetic alterations that are linked to response to EGFR-TKIs and ALK inhibitors, respectively.3, 4, 5, 136 EGFR has been demonstrated to be able to activate at least two major signaling pathways, including KRAS, which in turn activates BRAF and the MAPK cascade, and phosphatidylinositol 3-kinase (PI3K), which activates
Take-home messages
(1) Pathologists should be conscious that they play a key role in the management of patients with lung cancer in the era of new histology-based therapeutic agents (i.e., pemetrexed and bevacizumab) and targeted molecular therapies (i.e., EGFR inhibitors gefitinib and erlotinib and ALK inhibitor crizotinib).
(2) Pathologists are called to perform more precise subtyping of NSCLC, becoming familiar with immunohistochemistry (antibodies expression and its interpretation), and carefully select the
Acknowledgments
Given the editorial limits, we would apologize to all the authors of interesting original and review works not cited here.
References (143)
- et al.
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Lancet Oncol
(2010) - et al.
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Lancet Oncol
(2011) - et al.
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Lancet Oncol
(2012) - et al.
Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
Lancet Oncol
(2008) - et al.
Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study
Lancet Oncol
(2011) - et al.
New driver mutations in non-small-cell lung cancer
Lancet Oncol
(2011) - et al.
International association for the study of lung cancer/American Thoracic Society/European Respiratory Society International multidisciplinary classification of lung adenocarcinoma
J Thorac Oncol
(2011) - et al.
K-ras mutations in non−small-cell lung carcinoma: a review
Clin Lung Cancer
(2006) - et al.
EML4–ALK fusion is linked to histological characteristics in a subset of lung cancers
J Thorac Oncol
(2008) - et al.
Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component
Lung Cancer
(2011)
Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancer
Lung Cancer
Role of molecular studies in the diagnosis of lung adenocarcinoma
Mod Pathol
Mucinous differentiation correlates with absence of EGFR mutations and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features
J Mol Diagn
Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens
Mod Pathol
D (delta)Np63 (p40) and thyroid transcription factor-1 (TTF1) immunoreactivity upon small biopsies or cell blocks for typing non-small cell lung cancer: a novel two-hit, sparing-material approach
J Thorac Oncol
Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas
Mod Pathol
Pathology of lung cancer
Clin Chest Med
Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy
J Thorac Oncol
Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma
Lung Cancer
Effusion immunohistochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma
J Thorac Oncol
Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR
J Mol Diagn
Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations
J Thorac Oncol
Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry
Lung Cancer
The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma
Lung Cancer
Cancer statistics, 2012
CA Cancer J Clin
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
J Clin Oncol
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib
N Engl J Med
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
Science
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Proc Natl Acad Sci U S A
Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma
N Engl J Med
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
N Engl J Med
Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy
Clin Cancer Res
American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy
J Clin Oncol
Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
Ann Oncol
LUX-Lung 3: a randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations
J Clin Oncol
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Nature
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
N Engl J Med
Cosmic 2005
Br J Cancer
KRAS mutations in non–small cell lung cancer
Proc Am Thorac Soc
Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study
Clin Cancer Res
Phase II clinical trial of chemotherapy-naive patients ≥70 years of age treated with erlotinib for advanced non-small-cell lung cancer
J Clin Oncol
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
PLoS Med
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
PLoS Med
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer
Clin Cancer Res
Erlotinib in previously treated non-small cell lung cancer
N Engl J Med
Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer
J Clin Oncol
Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer
J Clin Oncol
Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma
Cancer
Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non–small-cell lung cancer
J Clin Oncol
Cited by (15)
La classification histo-pathologique des cancers bronchiques: que faut-il savoir pour un clinicien ?
2019, Revue des Maladies Respiratoires ActualitesStrategy for molecular testing in pulmonary carcinoma
2016, Annales de PathologieDiagnostic Pathology: Molecular Oncology: A volume in Diagnostic Pathology
2015, Diagnostic Pathology: Molecular OncologyBiomarkers in Pulmonary Carcinomas
2022, Biomarkers in Carcinoma of Unknown PrimaryIdentification and Characterization of SNP Mutation in Genes Related to Non-small Cell Lung Cancer
2021, Current Signal Transduction TherapyPrecision follow-up for resected non-small-cell lung cancer: Is it ready for prime time?
2021, European Journal of Cardio-thoracic Surgery